Faculty


Moderator
Workshop
"Molecular Biology in Breast Oncology"

Carlos L. Arteaga, MD
Professor and Director
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center

Dr. Arteaga obtained his MD degree at the University of Guayaquil in Ecuador. He trained in Internal Medicine and Medical Oncology at Emory University and the University of Texas Health Sciences Center San Antonio, respectively. He joined Vanderbilt in 1989 where he served as Associate Director for Translational/Clinical Research, Director of the Center for Cancer Targeted Therapies and the Breast Cancer Program of the Vanderbilt-Ingram Cancer Center (VICC). He has over 300 publications in the areas of signaling by growth factor receptors and oncogenes in breast tumor cells, development of targeted therapies and biomarkers of drug action and resistance, and investigator-initiated clinical trials in breast cancer. Since 2002, he directed the NCI-funded Vanderbilt Breast Cancer SPORE where he co-led several investigator-initiated clinical trials. His research is or has been funded by the National Cancer Institute, the American Cancer Society, the Department of Defense Breast Cancer Research Program, Stand Up 2 Cancer (SU2C), the Susan G. Komen for the Cure Foundation, and the Breast Cancer Research Foundation. He is member of the American Society of Clinical Investigation (1998) and the Association of American Physicians (2005). He served in the NCI Board of Scientific Counselors (1999-2004), NCI Parent Subcommittee A for review of Cancer Centers (2004-2008), the Breast Core Committee of the Eastern Cooperative Oncology Group (ECOG) and the Board of Directors of the American Association for Cancer Research (2004-2007). Arteaga is the recipient of the 2003 AACR Richard & Hinda Rosenthal Award, a 2007-2017 ACS Clinical Research Professor Award, the 2009 Gianni Bonadonna Award from the American Society of Clinical Oncology (ASCO), the 2011 Brinker Award for Scientific Distinction from the Komen Foundation, and the 2015 Prize for Scientific Excellence in Medicine from the American-Italian Cancer Foundation. He was elected Fellow of the American Association for the Advancement of Science (AAAS) in 2013 and Fellow of the AACR Academy in 2015, and serves in the Scientific Advisory Board of the Komen Foundation. He chaired the AACR Special Conference ‘Advances in Breast Cancer Research’ (2003-11) and has served as AACR co-chair of the annual San Antonio Breast Cancer Symposium since 2009. He was Deputy Editor of Clinical Cancer Research (2005-2013) and is member of the Editorial Board of Cancer Cell, Cancer Discovery and six other peer-reviewed journals. He serves in the advisory boards of several academic Breast Cancer Programs and NCI-designated Cancer Centers. He served as the 2014-2015 President of the American Association for Cancer Research, the largest cancer research organization in the world. In 2017, he was appointed as Director of the Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at UT Southwestern Medical Center.



Speaker
Special Session
"Weighing the benefits and harms of breast cancer screening"

Philippe Autier, MD, MPH, PhD
Vice-President, Population Research
International Prevention Research Institute 

Philippe Autier was born in Brussels, Belgium, and received a Doctor of Medicine degree from the Université Libre de Bruxelles and a diploma in tropical medicine from the Prince Leopold Institute of Tropical Medicine, Antwerp in 1983. He started his professional life by joining the humanitarian non-governmental organization Médecins Sans Frontières (MSF), where he helped in Honduras (1985 and 1986), and later in Chad (1987-88) as the medical coordinator of projects conducted by a team of approximately 50 expatriates and 200 Chadian health workers.

In 1988-89, Philippe Autier was the first head of the medical department of MSF-Belgium. He is one of the founders and a board member of the organisation AEDES that provides expertise in public health to low and middle income countries. In 1990 he received a Fulbright fellowship with a grant from the Frank Boas Foundation to study at Harvard School of Public Health, Boston, Massachusetts, where he was awarded an MPH. In 2011, he received a PhD from the Erasmus University in Rotterdam for his works on the cutaneous melanoma. Philippe Autier has been head of the Prevention and Screening Department of the Jules Bordet Institute in Brussels (1992-95 and 2002-2005), Deputy Director at the European Institute of Oncology in Milano (1995-2000), and Group Head at the International Agency for research on Cancer in Lyon (2000-2010). 

Philippe Autier is a leading figure in several fields including research on cutaneous melanoma and breast cancer, especially in domains related to the causation, prevention and early detection of these cancers. He is also very involved in the clinical testing of new methods for cancer detection and in health technology assessment. In the last ten years, Philippe Autier has embraced the domain of real world data and pharmaco-epidemiology, including the creation of collaborations with government-owned health-related databases and patient's registries.

In 2013 he was appointed Professor at Strathclyde University. Philippe Autier is Vice President, Population Research, at the International Prevention Research Institute.



Speaker
The Year in Review
"Translational research"

Justin Balko, PharmD, PhD
Associate Professor of Medicine and Pathology, Microbiology and Immunology
Vanderbilt University Medical Center

Justin M. Balko obtained his Doctorate in Pharmacy from the State University of New York at Buffalo in 2004.  After completion of his PhD in the Clinical and Experimental Therapeutics track of the Pharmaceutical Sciences program at the University of Kentucky in Lexington, KY, he joined the laboratory of Carlos L. Arteaga, MD, in 2009 as a postdoctoral research fellow.

Dr. Balko was appointed as Assistant Professor of Medicine in January of 2015 and promoted to Associate Professor of Medicine and Pathology, Microbiology, and Immunology in February of 2020.  He has published approximately 90 papers in the field of molecular oncology and translational oncology research, primarily in the breast cancer field.  His laboratory focuses on identifying biomarkers and mechanisms of drug sensitivity or resistance in breast cancer and other tumor types, ways to enhance response rates to immunotherapy by targeting cancer-specific signals of immune suppression, and the biological mechanisms of immune-related adverse events to immunotherapies. His laboratory receives funding from the NIH/NCI, the Department of Defense, The IBC Network Foundation, the Jimmy V Foundation for Cancer Research, The Mary Kay Foundation, Stand Up 2 Cancer/AACR, and Susan G. Komen.  He is currently a correlative sciences Principal Investigator on several breast cancer trials employing combinations of molecularly-targeted agents with immunotherapy.  



Speaker
Translational Science Forum
"What's available now and what's on the horizon (Early development)"

Aditya Bardia, MBBS, MPH
Attending Physician
Massachusetts General Hospital
Harvard Medical School

Dr. Aditya Bardia, a board-certified medical oncologist, is an Attending Physician at Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston. As the Director of Precision Oncology Program at the MGH Center for Breast Cancer, Dr. Bardia is interested in integrating precision diagnostics and therapeutics, including clinical application of circulating tumor cells and DNA as “liquid biopsy”, to significantly improve the outcomes of patients afflicted with breast cancer. Dr. Bardia has led the clinical development of antibody drug conjugate (ADC), sacituzumab govitecan, and selective estrogen receptor degrader (SERD), elacestrant, in metastatic breast cancer. Dr. Bardia has received several research awards including outstanding award for research excellence at Mayo Clinic, Young Investigator Award from ASCO, and Douglas Family Foundation prize for excellence in oncology research at MGH. Dr. Bardia is the editor of precision medicine clinic section of The Oncologist, co-leader of the Molecular and Precision (MAP) tumor board at MGH, and editorial board member of ASCO TAPUR. 



Speaker
Educational Session
"Evolution and heterogeneity"

Andrea Bild, PhD
Professor, Department of Medical Oncology and Therapeutics
City of Hope

Dr. Andrea Bild is experienced in genomic analysis of breast cancer and uses systems biology to measure response to therapy. 



Speaker

Educational Session
"Targeting DDR"

Simon Boulton, PhD
Senior Group Leader
Francis Crick Institute and Artios Pharma Ltd.

Simon Boulton is a senior group leader at the Francis Crick Institute. His research is focused on understanding DNA repair mechanisms, with emphasis on DNA double stand break (DSB) repair pathways and their utilization in meiosis, during DNA replication and at telomeres. His work using genetics, biochemistry and biophysical approaches has led to the discovery of novel DNA repair genes and provided molecular insights into human diseases, including cancer. Most notably, Boulton’s work has played an instrumental role in shaping our understanding of the regulation and execution of homologous recombination (HR), a key DSB repair pathway frequently inactivated in cancer. Boulton is also Scientific Co-founder and SVP Science Strategy of Artios Pharma Ltd, which is developing small molecule DNA repair inhibitors to selectively kill cancer cells either as mono-therapies or in combination with existing treatments. Boulton has helped raise $130m private and strategic investment for the company and currently assist the executive team in the identification and evaluation of new pipeline opportunities from the global DNA repair network. The companies leading two assets, ATR and POLQ inhibitors, will enter clinical trials in early 2021. 



Speaker

Workshop
"Improving clinical trial design"

Thomas Braun, PhD
Professor
University of Michigan School of Public Health

Dr. Thomas Braun is a leading expert in the design of adaptive Phase I clinical trials, having published numerous applied and methodologic manuscripts in this area for approximately 20 years. He has also been the primary statistician for the University of Michigan Rogel Cancer Center Blood and Marrow Transplantation (BMT) Program for 20 years and has expert knowledge in the design and analysis of data from clinical trials and basic science experiments for the study of hematopoietic cell transplantation (HCT) and graft-versus-host-disease (GVHD). He has also collaborated extensively in the analysis of data collected on adults with breast and lung cancer, and he is very familiar with the use of immunotherapy for the treatment of both diseases.



Speaker

Clinical Science Forum
"Understanding current platforms"

Mark E. Burkard, MD, PhD
Professor of Medicine and Oncology
University of Wisconsin - Madison

Dr. Burkard is Professor of Medicine and Oncology at the University of Wisconsin.  He serves as Associate Director of Genomics and Precision medicine and, in this role, coordinates cancer precision medicine activities across the UW Health system and state-wide partners.  He completed his MD and PhD in chemistry as part of the University of Rochester Medical Scientist Training Program.  Thereafter, he completed Internal Medicine Training and New York Hospital/Cornell, followed by Medical Oncology training at Memorial Sloan Kettering Cancer Center in 2008.  At the University of Wisconsin, he leads a federally-funded laboratory program in breast cancer cell biology and has authored, or coauthored 42 publications.  His group has been active in patient engagement, through the Outliers project, which focuses on genomics of individuals who are extreme survivors with metastatic breast cancer.  In 2015, he co-founded the Precision Medicine Molecular Tumor Board,  which reviews over 1400 precision medicine cases per year across regional health systems, and coordinates the associated precision medicine trials at UW Carbone Cancer Center.  He has received the Dean's Teaching Award, the Page-Grossman Professional Award, and the Vilas Mid-Career Investigator Award, and has been an invited speaker in precision oncology across the U.S. and internationally at the Asia-Pacific Breast Cancer Summit.  He serves as a member of the ASCO/TAPUR Molecular Tumor Board, associate editor of Breast Cancer Research and Treatment, and is a member of the Strata Oncology Clinical Advisory Board.



Speaker

Educational Session
"Special topics in early stage ER+ breast cancer "

David Cameron, MBBS, MD
Professor of Medical Oncology
The University of Edinburgh



Speaker

Educational Session
"State of the art treatment for neoadjuvant/adjuvant triple negative breast cancer"

Lisa A. Carey, MD
Jacobs Preyer Distinguished Professor for Breast Cancer Research
University of North Carolina
Lineberger Comprehensive Cancer Center

Lisa Carey’s research interests focus upon breast cancer, including examination of different subtypes of breast cancer, evaluation of new chemotherapy agents in early and metastatic breast cancer, and examination of tumor characteristics that predict response to therapy.

She has worked extensively with scientists across UNC Lineberger and the UNC Gillings Global School of Public Health to better understand and characterize the molecular subtypes of breast cancer so that we may develop better prevention and treatment strategies. With Drs. Perou and Millikan, she identified the elevated risk of the poor-prognosis basal-like breast cancer subtype in young African-American women. She is a world-wide expert in triple negative breast cancer, and led the first trial looking at a new drug regimen in this breast cancer subtype.

Her research spans the spectrum from early curative breast cancer to metastatic disease. She has worked extensively developing trials that use neoadjuvant, or preoperative, chemotherapy for breast cancer in order to address both clinical questions about the best regimens, as well as scientific questions regarding sensitivity or resistance to drugs. She led a large NCI-sponsored trial in HER2-positive breast cancer that examined dual HER2-targeting with two anti-HER2 drugs that found that while drug regimen was important in outcome, even more important were tumor characteristics such as subtype and evidence of immune cell activation. Based on this work, she has put together an international team looking at the molecular markers responsible this variation in response and survival, and her efforts as co-chair of the national cooperative group, Alliance, have resulted in two NCI trials examining these markers and optimizing treatment. In addition, she is actively involved in examining novel agents in metastatic breast cancer. Her Tumor Donation Program has contributed novel information regarding the genetic differences between the original primary breast cancer and the metastases in distant organs. This work in part spawned the AURORA-US multicenter initiative furthering this examination of the molecular landscape of metastatic disease; she serves on the Steering Committee for that effort.

She serves in national leadership roles, including as a member of the National Cancer Institute Breast Cancer Steering Committee, Co-Chair of the NCI-sponsored Alliance Breast Committee, Co-Chair of the Translational Breast Cancer Research Consortium Steering Committee, and member of the Board of Directors of the American Society of Clinical Oncology.



Speaker
Educational Session
"Treatment differences and consequences"

Mariana Chavez MacGregor, MD, MSC
Associate Professor 
UT MD Anderson Cancer Center

Dr. Mariana Chavez MacGregor is a medical oncologist with a clinical practice dedicated to the care of patients with breast cancer. After finishing medical school at the Universidad Nacional Autónoma de México, she obtained a Master in Sciences degree in Clinical Epidemiology at the Netherlands Institute of Health and Sciences.  She completed her Clinical Residency in Internal Medicine at Barnes-Jewish Hospital/Washington University School of Medicine followed by a Clinical Fellowship in Medical Oncology at The University of Texas MD Anderson Cancer Center. She is an Associate Professor at The University of MD Anderson Cancer Center, holding a primary appointment in the Health Services Research Department, and a joint appointment in the Breast Medical Oncology Department. 

In addition of being an active and compassionate clinician, Dr. Chavez MacGregor is committed to an academic a career. She has received a number of awards including the SWOG Young investigator award and the Multinational Association of Supportive Care in Cancer (MASCC) Young Investigator of the Year award. She received the Achievement in Clinical Research Award and was recently honored with the MD Anderson Faculty Scholar Award. She holds leadership positions within ASCO, currently serving as the past-chair of the Clinical Practice Guidelines Committee. Dr. Chavez MacGregor research focuses on breast cancer outcomes and disparities research. She has extensive experience evaluating patterns of care, toxicities and complications of cancer treatment. In addition, she has been involved in the planning, design and implementation of clinical trials and is an active member of SWOG. 

She has written more than 100 articles, review articles, invited commentaries, and book chapters on breast cancer.



Moderator
Basic Science Forum
"The Tumor and Immune Ecosystem of Breast Cancer"

Chonghui Cheng, MD, PhD
Associate Professor 
Baylor College of Medicine

Dr. Chonghui Cheng has received several prestigious awards throughout her professional career, including the Julian R. Rachele Award of Excellence and the Frank Lappin Horsfall, Jr. Fellowship as a PhD student, the Postdoctoral Fellowship from the Damon Runyon Cancer Research Foundation, the Career Development Awards from the Schweppe Foundation and from AACR, the ACS Research Scholar Grant, the Lynn Sage Scholar, and the Rising-Star CPRIT Scholar in Cancer Research from Texas.

She has been a scientific reviewer for top-tier journals and for study sections in NCI, ACS, AACR and is currently a Medical Advisory Board member in the Lynn Sage Foundation. During her tenure at Northwestern University, she was Program Leader of the Tumor Invasion, Metastasis, and Angiogenesis Program at the Robert H. Lurie Comprehensive Cancer Center (RHLCCC). Dr. Cheng organized several symposiums including the annual cancer center symposium at RHLCCC, was Faculty Search Committee member,  Chair of Travel Fellowship Review Board, and Course Director of the Tumor Cell Biology graduate course. Currently at Baylor College of Medicine since 2016, she serves as a co-organizer of the Lester and Sue Smith Breast Center Annual Retreat, Graduate Education Program member in the Department of Molecular and Human Genetics, Platform Judge of the Annual Department of Molecular & Cellular Biology Graduate Students Symposium, and a member in two Faculty Search Committees. She also chaired an RNA and Disease Workshop in the 2015 international RNA Society Annual Meeting and will be chairing the Basic Science Forum in the 2020 SABCS.

Her research interests are centered at understanding how RNA regulation affects breast cancer cell plasticity, resulting in tumor metastasis and therapeutic resistance. They are also pushing forward the research in circulating tumor cells (CTCs)and pioneering the RNA sequencing of CTCs. Dr. Cheng has been invited to give seminars at major Universities in the US, including Columbia University, UCLA, UCSD, MD Anderson, Emory University, etc. and is a regular presenter at national and international meetings, including the RNA Society Annual Meeting, the EMT International Association Meeting, and the Metastatic Breast Cancer Conference, etc. 



Speaker
Educational Session
"Dormancy"

Lewis A. Chodosh, MD, PhD
Perelman Professor in Cancer Biology
University of Pennsylvania 



Speaker
Educational Session
"Special topics in mechanisms of therapeutic resistance"

Robert Clarke, PhD
Professor of Breast Biology
Manchester Breast Centre



Speaker
Workshop
"Increasing clinical trial accrual"

Deborah Collyar, PhD
Founder and President
Patient Advocates in Research (PAIR)



Speaker
Educational Session
"How and when to use immunotherapy and related toxicities"

Javier Cortes, MD, PhD
Head Breast Cancer Program
IOB Institute of Oncology, Madrid and Barcelona

Head of the Breast Cancer and Gynecological Tumor teams at the Ramón y Cajal University Hospital in Madrid, as well as Clinical Investigator of the Breast Cancer Research Program at the Vall d'Hebrón Institute of Oncology in Barcelona. The breast cancer program at the Oncological Institute (IOB) is also directed by Dr. Javier Cortés and is one of the most active in Spain and one of the most renowned in all of Europe.

He has been part of the development of the 4 approved drugs for metastatic breast cancer in Europe for the last 5 years. His group has led the fundamental trials that led to the approval of 3 out of 4 of these agents: pertuzumab, eribulin, and everolimus. Dr. Cortés is one of the European leaders in the field of HER2 + breast cancer. He is very involved in understanding the different mechanisms of resistance to treatment. Currently, he is leading one of the most exciting trials with cyclin D 4/6 inhibitors, a new group of compounds with surprising activity when combined with endocrine therapy.

Immunotherapy is also an area in which Dr. Cortés is very involved, mainly in the triple negative subtype. This could become a potential curative therapeutic approach for a significant number of patients with metastatic triple negative breast cancer in the future.It is part of more than 50 breast cancer projects, with a leadership position in more than 50% of them, including phase I to phase III studies. He hopes to have at least 6 to 8 new compounds in the next 5 years in the field of breast cancer.

Active member of the Spanish, European and American Societies of Medical Oncology (SEOM, ESMO, ASCO) and member of the Scientific Committee of the European Society of Medical Oncology.  

With a true passion for patient treatment, she is very interested in the patient's experience and cares about improving her quality of life. He hopes to cure most breast cancer patients in the coming years and is actively involved in cancer research to this end. 

Dr. Javier Cortés has a degree in Medicine and Surgery from the Autonomous University of Madrid in 1996. He continued his studies at the University of Navarra, specializing in Medical Oncology at the University Clinic of Navarra. Since 2003 he has worked in the Department of Medical Oncology at the Vall d'Hebron Hospital in Barcelona, where he has been Coordinator of the Teaching and Training Program for Residents in Oncology and Senior Specialist in the Area of Breast Cancer with a special interest in the Development of New Medicines. Dr. Cortés was the Director of the Breast Cancer Program and the Melanoma Unit from July 2006 to August 2015. He is also the author of more than 140 publications, more than 300 presentations and is an ad hoc reviewer for several magazines.



Speaker
Educational Session
"New insights to cancer-associated systemic inflammation"

Karin de Visser, PhD
Group Leader Division of Tumor Biology and Immunology
Netherlands Cancer Institute 



Moderator
Educational Session
"Triple Negative Breast Cancer"

Speaker
Educational Session
"Deconstructing TNBC"

Speaker
Year in Review
"Advanced breast cancer"

Rebecca Dent, MD, MSc
Head and Senior Consultant Medical Oncology
National Cancer Center Singapore
Duke - NUS Medical School

Dr. Rebecca Dent's primary research interest is in the field of breast cancer, with a focus on locally advanced breast cancer and triple negative (TNBC)/basal-like breast cancers. She served as Chair of the locally advanced breast cancer program and Head, Breast Cancer Clinical Trials at the Sunnybrook Odette Cancer Center in Toronto, Ontario Canada from 2008-2011. 

Since beginning her position in February 2011 as a consultant and now senior consultant and Head of Department of Medical Oncology at the National Cancer Center in Singapore, she has founded and co-chaired eight Asia Pacific Breast Cancer Summits. This is a multidisciplinary meeting for the treatment of breast cancer in which they are able to attract over 500 attendees from over 25 countries in the Asia Pacific region. She is a steering committee member and PI for a number of large international trials in TNBC. They have secured funding for an investigator initiated global study evaluating the role of PARP inhibition with or without immune checkpoint inhibition in platinum sensitive TNBC. This is a Duke-Singapore Duke-USA collaborative trial. Finally. Dr. Dent has served on a number of international committees such as the American Society of Clinical Oncology Scientific Committee (ER/HER2 track), Education Chair Breast Track ASCO Annual Meeting, Scientific Committee Chair of European Society of Medical Oncology (ESMO) Asia and Chair, ESMO Metastatic Breast Track 2019 in Barcelona, and Scientific Committee Member ASCO Breakthrough Asia Meeting, Bangkok.



Panelist
View From The Trenches - What Will You Do On Monday Morning?

Peter Dubsky, MD, PhD
Head of Breast Center
Hirslanden Klinik St. Anna Breast Center

Peter Dubsky was born in Vienna and was schooled in Germany, London and New York City. He received his MD from the University of Vienna in 1997 and began his surgical training at the University Clinic. He completed a post-doctoral fellowship in cancer immunology (Baylor Institute for Immunology Research, Dallas, Texas, USA) between 2002 and 2004.  After board certification in General Surgery in 2005, he focused his work on surgical oncology and was promoted to Senior Consultant at the Medical University of Vienna (MUV) in 2007. He continues to serve in Vienna as adjunct Professor of Surgery. Furthermore, he continues his long-time commitment to the Austrian Breast and Colorectal Cancer Study Group (ABCSG) and currently serves on their executive committee.

Starting April 2016 Dr. Dubsky has built the Breast Cancer Center at the Hirslanden Clinic St. Anna in Lucerne, Switzerland. Since then he has established full certification of the breast center and continues to build a Cancer Center for St. Anna Clinic. He also founded the Network of Hirslanden Breast Cancer Centers (NHBCC) and a Consensus Conference with a focus on surgery after primary systemic therapy during this time.

Dr. Dubsky has authored or co-authored more than 100 scientific publications with a total citation count of over 5000 and author h-index >40. Most of his work focuses on clinical trials in early breast cancer and biomarkers.  Since 2015 he has joined the faculty of the St. Gallen International Breast Cancer Conference since 2016 both as panelist and member of the consensus writing committee. In addition to the SABCS 2020, he has  has joined the ASCO and ESMO faculty of 2020.



Moderator
Clinical Science Forum
"Next Generation Sequencing in Clinical Practice"

Matthew J. Ellis, MB, BChir, BSc., PhD, FRCP
Director
Lester and Sue Smith Breast Center
Baylor College of Medicine

Dr Matthew James Ellis a physician scientist who completed his training at the University of London (PhD) and the University of Cambridge (MB BChir).  He is currently the Director for the Lester and Sue Smith Breast Center at Baylor College of Medicine where he coordinates an interdisciplinary team of oncologists, pathologists, epidemiologists, basic scientists and statisticians focused on improving our ability to prevent, detect and treat breast cancer.  In addition, he is the Associate Director for Translational Research at the Dan L. Duncan Comprehensive Cancer Center, with a broad role in promoting translational research.  His research has focuses on estrogen receptor positive (ER+) breast cancer. He has championed neoadjuvant endocrine therapy as a non-toxic alternative to chemotherapy for promoting breast-conserving therapy in postmenopausal women with ER+ HER2- stage 2 and 3 disease (Journal of Clinical Oncology 2001).  He developed the Ki67 proliferation marker-based Preoperative Endocrine Prognostic Index (Journal of Clinical Oncology 2017) that is now undergoing a large validation study (the ALTERNATE study).  These clinical studies have provided the context and tumor specimens for seminal investigations into the ER+ breast cancer somatic genome, with insights into clonal heterogeneity (Nature Communications 2015), new tumor suppressor gene discovery specific to ER+ disease and new therapeutic targets (Nature 2012).  These include activating mutations in the HER2 gene that have been shown respond to HER2 kinase inhibition in clinical trials, particularly metastatic lobular carcinoma (Cancer Discovery 2013, Clinical Cancer Research 2017).  He also is a pioneer of patient-derived xenograft research (PDX).  A PDX study in triple negative breast cancer revealed clonal remodeling during brain metastasis (Nature 2010).  PDX analysis also revealed acquired resistance to endocrine therapy is a consequence of ESR1 ligand-binding mutation; ESR1 amplification and most uniquely chromosomal translocation causing fusions between the N terminus of ESR1 and the C-terminus of genes that can confer constitutive transcriptional activity (Cell Reports 2013).  To improve our ability to understand the complex genomic changes he has been working with the Clinical Proteomic Tumor Analysis Consortium at the US National Cancer Institute to develop proteogenomic analysis of breast cancer.  This mass spectrometry-based approach recently elucidated the functional consequences of somatic mutations, narrowed candidate nominations for driver genes within large deletions and amplified regions and identified therapeutic targets (Nature 2016, Nature Communications 2017).  His work has been cited over 30,000 times (Google Scholar).  Laboratory web page https://www.bcm.edu/research/labs/matthew-ellis



Speaker
Workshop
"Capturing patient reported outcomes"

Oluwadamilola Fayanju, MD, MA, MPHS, FACS
Assistant Professor of Surgery
Duke University School of Medicine



Moderator
Educational Session
"Metastasis -  A Moving Target"

Suzanne AW Fuqua, PhD
Professor 
Baylor College of Medicine

Dr. Suzanne Fuqua received her Bachelor and Master of Science degrees from the University of Houston, and her PhD in Cancer Biology from the MD Anderson Cancer Center in Houston, Texas.  She joined the University of Texas Health Science Center at San Antonio as a postdoctoral fellow in 1985, attaining the position of tenured Associate Professor in 1994.  She moved with this breast cancer research group to the Baylor College of Medicine in 1999, where she was promoted to the rank of tenured Professor of Medicine.  Dr. Fuqua holds a joint-appointment in the Department of Molecular and Cellular Biology, is a faculty member of the Lester and Sue Smith Breast Center, and is Associate Director of Education and Training at the Dan L Duncan Comprehensive Cancer Center.  Dr. Fuqua has published over 100 papers in peer-reviewed journals, and has authored 50 Books/Chapters. She is internationally known for her research on the discovery of mutant estrogen receptors in metatastic breast cancer, and their clinical significance in breast cancer progression and resistance to hormonal therapies in estrogen receptor-positive breast cancer.  



Moderator
Educational Session
"Special Topics in ER+ Breast Cancer"

Matthew P. Goetz, MD
Professor of Oncology and Pharmacology
Mayo Clinic

Matthew P. Goetz, MD is a consultant in the Division of Medical Oncology, Department of Oncology, at Mayo Clinic in Rochester, Minnesota. Dr. Goetz joined the staff of Mayo Clinic in 2003 and holds the academic rank of professor of oncology and pharmacology, Mayo Clinic College of Medicine and Science. He is recognized with the distinction of the Erivan K. Haub Family Professorship in Cancer Research Honoring Richard F. Emslander, MD.

Dr. Goetz received his B.A. in music at Wheaton College and his M.D. at the University of North Dakota School of Medicine. He completed an internship in internal medicine and a residency in internal medicine at the University of Michigan in addition to a postdoctoral fellowship in hematology and oncology at Mayo Clinic School of Graduate Medical Education.

He leads breast cancer research activities at Mayo Clinic where he is chair of the Mayo Breast Cancer Disease Group, co-leader of the Women’s Cancer Program within the Mayo Clinic Cancer Center, and Director of the Mayo Breast Cancer SPORE. 

Dr. Goetz has been extensively involved in both translational research as well as in the conduct of early- and late-phase clinical trials, with a focus on germline and tumor factors that alter endocrine responsiveness. A notable area of research focus has been the pharmacogenetics of tamoxifen, where Dr. Goetz has led multiple studies demonstrating the importance of CYP2D6 genetic variation as a predictor of tamoxifen response, resulting in Clinical Pharmacogenetics Implementation Consortium guidelines for use of CYP2D6 genotype for tamoxifen dosing. Emanating from this work, and in collaboration with the Developmental Therapeutics Program of the National Cancer Institute (NCI), Dr. Goetz has led a team of investigators in the development of a novel formulation of endoxifen for the treatment of estrogen receptor positive breast cancer through both phase I and II clinical studies.   

Matthew Goetz also worked to develop prospective “multi-omic” prospective studies including the Breast Cancer Genome-Guided Therapy (BEAUTY) and PROMISE studies, wherein blood and tumor biopsies are obtained for comprehensive “omic analyses’ and patient derived xenografts (PDX).  Together, the combined “omic”, PDX, and clinical trial outcome data provide a resource to drive new therapeutic approaches for treatment resistant breast cancer.

In addition to his clinical and research roles, Dr. Goetz is active in professional organizations. He currently serves on committees and panels for the Clinical Pharmacogenetics Implementation Consortium, the National Comprehensive Cancer Network, the NCI Breast Cancer Steering Committee, and the Translational Breast Cancer Research Consortium 



Speaker
Educational Session
"Obesity, inflammation and breast cancer - what's new"

Pamela Goodwin, MD, FRCPC
Medical Oncologist and Clinician Scientist
Mount Sinai Hospital

Dr. Goodwin has been involved in the field of translational breast cancer research, with a focus on the association of obesity with breast cancer outcomes, for more than 25 years. She has focused on investigating the role of obesity associated factors, such as insulin resistance, glucose and inflammatory markers that may mediate the obesity-breast cancer association. They have confirmed adverse prognostic associations of obesity in breast cancer and identified metabolic factors (insulin/glucose/insulin resistance) as potential mediators. Based on these observations, Dr. Goodwin has initiated a number of trials in the adjuvant and metastatic breast cancer settings to investigate the potential benefits of metformin, an oral diabetes drug that lowers circulating insulin levels, improves glucose and reduces inflammation, on breast cancer outcomes. More specifically, she is the Principal Investigator of a major international adjuvant study of metformin in early breast cancer (CCTG MA.32) being run through the Canadian Cancer Trials Group and the Cancer Therapy Evaluation Program (NCI). They have completed enrollment of 3649 women, reported planned early analyses of the effect of metformin on physiologic factors, and anticipate final results in 2021. More recent work has focused on the identification of factors associated with late recurrence.



Panelist
View From The Trenches - What Will You Do On Monday Morning?

William J. Gradishar, MD
Professor of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University

Dr. Gradishar’s clinical domain is breast cancer management. His clinical research interest focuses on the development of novel therapies for the treatment of breast cancer. Clinical trials focusing on precision medicine for defining the right therapy, for the right patient at the right time is our goal. To that end, molecular interogation of breast tumors are leading to novel trial design that will hopefully translate into better outcomes for our patients. In conjuction with the developmental therapeutics program, novel agents are being incorporated into clinical trials for patients with both early and late stage disease.



Speaker
Year in Review
"Early breast cancer"

Erika Hamilton, MD
Director, Breast and Gynecologic Cancer Research Program
Sarah Cannon Research Institute 

Dr. Hamilton joined Sarah Cannon in 2013. Dr. Hamilton cares for patients with breast and gynecologic cancer. As the director of the breast cancer and gynecologic cancer research program, she oversees the program and the clinical trial menu for these cancers across the Sarah Cannon network.  

After receiving an undergraduate degree from Washington and Lee University in Virginia, Dr. Hamilton completed her medical degree and residency from University of North Carolina in Chapel Hill. She received her fellowship training in hematology and oncology from Duke University in Durham, North Carolina, where she was recognized as a Top 5 Finalist for Duke's Annual House staff Fellow Teaching Award. She is board certified in internal medicine and oncology. Additionally, she is a partner with Tennessee Oncology, PLLC.



Speaker
Mini Symposium
"APOBEC"

Reuben Harris, BSc, PhD
Professor
Howard Hughes Medical Institute (HHMI)
University of Minnesota

Dr. Harris is an Investigator at the Howard Hughes Medical Institute and a Professor of Biochemistry, Molecular Biology and Biophysics, the Associate Director of the Institute for Molecular Virology, and a Member of the Masonic Cancer Center at the University of Minnesota. He received his B.S. (1993) and Ph.D. (1997) degrees from the University of Alberta and performed postdoctoral work at Baylor College of Medicine (1997-1998), Yale University (1998), and Cambridge University (1998-2003). He joined the University of Minnesota as an Assistant Professor in 2003 and was promoted to Associate Professor with Tenure in 2008 and to Full Professor in 2013. Dr. Harris has received numerous grants and awards, including a Searle Scholarship, American Academy of Microbiology Fellowship, American Association for the Advancement of Sciences Fellowship, and a Distinguished McKnight University Professorship. In 2015, he was appointed as a Howard Hughes Medical Institute Investigator. Dr. Harris is an Associate Editor for Science Advances and an Editorial Board Member for Journal of Biological Chemistry, Journal of Virology, and Cancer Research. He has published over 180 manuscripts, contributed to 13 patent applications, and co-founded a cancer therapeutics company.

Dr. Harris’s scientific passion is elucidating mechanisms of mutation and establishing relevance to human biology and disease. As a doctoral student, he discovered a novel recombination-dependent mutation process operative in stationary-phase bacteria with implications for antibiotic resistance and microbial evolution. As a postdoctoral fellow, he helped solve an immunology Rosetta stone by discovering the DNA cytosine deaminase activity of AID and proposing a DNA deamination model for antibody gene diversification. Also as a postdoctoral fellow, he discovered the DNA cytosine deaminase activity of several APOBEC family members and, during the transition to faculty, elucidated a new mechanism of antiviral immunity by demonstrating APOBEC3G-catalyzed retroviral cDNA hypermutation. As a Principal Investigator, Dr. Harris has become known for his work on APOBEC enzymes in antiviral immunity, including discovering multiple APOBEC3s in HIV-1 restriction, demonstrating the mechanism by which HIV-1 Vif degrades APOBEC3 proteins, and elucidating the first structures of APOBEC-ssDNA complexes. This body of work has shed light on fundamental mechanisms of antiviral immunity and yielded new strategies for drug development.

In recent years, Dr. Harris’s virology studies have enabled a major breakthrough in cancer research. His group found that APOBEC3 enzymes are responsible for a large proportion of mutations in breast, head/neck, lung, bladder, cervical, and other cancers. Independent work has confirmed these results and indicated that “APOBEC mutagenesis” far exceeds most other sources of mutations in cancer, including those attributable to smoking and UV rays. His team continues to investigate the molecular mechanism of APOBEC-driven cancer mutagenesis in cancer and develop new methods to better diagnose and treat APOBEC-positive tumors. Please see http://harris.cbs.umn.edu for more information on Dr. Harris’s research program.



Speaker - Pro
Educational Session
"Exceptional responders to neoadjuvant chemotherapy"

Joerg Heil, MD, PhD
Head of Breast Unit
University Hospital Heidelberg

As head of the Heidelberg Breast Unit Prof. Heil is in charge to organize all teaching activities for students as well as residents in the field of breast cancer and serves as an adviser and programm commitee member of the German breast cancer symposium (Senologiekongress) where he usually moderate some sessions on breast surgerical oncology topics. German authorities and the German Society of Senology (Deutsche Gesellschaft für Senologie) and the University of Heidelberg awarded different teaching and research certificate and awards to him. Moreover Prof. Heil reviewed many scientific manuscript for a number journals (e. g. European Journal of Cancer, Annals of Oncology, Annals of Surgical Oncology, etc.)



Speaker
Educational Session
"Toxicities of breast cancer treatment"

Norah Lynn Henry, MD, PhD
Associate Professor
University of Michigan 



Panelist
"View From The Trenches - What Will You Do On Monday Morning?"

Alice Ho, MD, MBA
Radiation Oncologist
University of Pennsylvania 

Dr. Alice Ho, MD, MBA is a faculty member in Radiation Oncology at Massachusetts General Hospital and Associate Professor of Radiation Oncology at Harvard Medical School. She graduated from Tufts University School of Medicine and completed her residency in Radiation Oncology at Mount Sinai Medical Center in New York. She has served as faculty at Memorial Sloan-Kettering Cancer Center and Cedars-Sinai Medical Center. 

Dr. Ho is an experienced clinician researcher whose expertise lies in designing and conducting clinical trials that that examine rationale combinations of radiation with immune therapy and DNA repair-based therapy in breast cancer patients. Her other research interests focus on developing novel radiation techniques and identifying biomarkers as surrogates for early detection of toxicities in breast cancer patients receiving radiotherapy, particularly in women receiving breast reconstruction and radiation. She has expertise in all aspects of novel radiation techniques, including volumetric modulated arc therapy, intensity-modulated radiation therapy and proton therapy. 



Panelist
"View From The Trenches - What Will You Do On Monday Morning?"

Sara A. Hurvitz, MD, FACP
Professor of Medicine
University of California, Los Angeles
Jonsson Comprehensive Cancer Center

Sara A Hurvitz, MD, is Professor of Medicine at the University of California, Los Angeles (UCLA); co-director of the Santa Monica-UCLA Outpatient Oncology Practice; Medical Director of the Clinical Research Unit of the Jonsson Comprehensive Cancer Center at UCLA; and Director of Breast Oncology. Dr. Hurvitz earned her MD from the University of Southern California. She served internship/residency at UCLA 1999-2002, was Chief Resident of internal medicine 2003-2004 and completed a hematology-oncology fellowship at UCLA in 2006. Dr. Hurvitz earned board-certification in internal medicine, hematology, and medical oncology. 

Since joining the faculty at UCLA, Dr. Hurvitz has gained international recognition as an academic expert in breast oncology. She not only has an active clinical practice, but also has extensive experience designing and leading first-in-human through phase III clinical trials. She has served as UCLA principle investigator on over 50 interventional clinical trials, has been chair of six international and four national studies, on the steering committee for 15 international trials and on the Data Safety Monitoring Board for four studies of novel therapeutics. She has personally designed, co-written, obtained funding and completed multiple phase II and III clinical trials of novel targeted therapies (including “TRIO B07,” “KRISTINE” and “neoMONARCH”). She serves on the Department of Defense Breast Cancer Research Program Programmatic Panel, is on the Scientific Committee for TRIO (Translational Research in Oncology, formerly “BCIRG,” an academic not-for-profit academic clinical research organizattion), is on the editorial board for several peer-reviewed journals, including Journal of Clinical Oncology, and serves as an ad hoc reviewer for numerous high impact medical journals including the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, JAMA-Oncology, and Clinical Cancer Research. In addition to her expertise in the clinical development of novel therapeutics, Dr. Hurvitz also has been extensively involved in laboratory-based research. She has been awarded and successfully led and completed several government-funded basic science projects. Additionally, she co-directs the preclinical evaluation of novel targeted therapeutics for breast cancer in the UCLA-JCCC/Translational Oncology Research Laboratory (TORL).  Dr. Hurvitz is committed to the translation of basic laboratory science into innovative clinical testing and the movement of important clinical questions into the laboratory.  Her understanding of both bench and bedside makes her uniquely positioned to lead the successful translation of new discoveries into the clinical realm.



Speaker - Pro
Educational Session
"DCIS"

E. Shelley Hwang, MD, MPH
Surgical Oncologist
Duke University  



Speaker
Educational Session
"Omitting radiotherapy in select situations"

Reshma Jagsi, MD, DPhil
Newman Family Professor & Deputy Chair, Department of Radiation Oncology
University of Michigan

Reshma Jagsi, M.D., D.Phil., is Professor and Deputy Chair in the Department of Radiation Oncology and Director of the Center for Bioethics and Social Sciences in Medicine at the University of Michigan.  She graduated first in her class from Harvard College and then pursued her medical training at Harvard Medical School.  She also served as a fellow in the Center for Ethics at Harvard University and completed her doctorate in Social Policy at Oxford University as a Marshall Scholar.  Dr. Jagsi’s medical research focuses on improving the quality of care received by breast cancer patients, both by advancing the ways in which breast cancer is treated with radiation and by advancing the understanding of patient decision-making, cost, and access to appropriate care.  Her social scientific research includes research into issues of bioethics arising from cancer care and research regarding gender issues, including studies of women's representation in the medical profession.  She is the author of over 200 articles in peer-reviewed journals, and her research has been funded by the National Institutes of Health, the American Cancer Society, the Robert Wood Johnson Foundation, and other philanthropic foundations.  She serves as the radiation oncology liaison for the Breast Committee of SWOG and as a representative on the National Cancer Institute’s BOLD task force, and she is also active in NRG and the TBCRC.  She has been elected to the Board of Directors of ASCO and serves on numerous other influential national professional committees. 



Moderator
Educational Session
"Genomic and Epigenomic Alterations in Resistance"

Speaker
Educational Session
"The unique epigenetic state of invasive lobular breast cancers"

Rinath Jeselsohn, MD
Instructor in Medicine
Dana-Farber Cancer Institute  



Speaker
Educational Session
"Strategies to reduce cardiac toxicity"

Rachel B. Jimenez, MD
Radiation Oncologist
Massachusetts General Hospital

Rachel Jimenez, MD is an Assistant Professor at Harvard Medical School and a breast radiation oncologist at Massachusetts General Hospital. Dr. Jimenez obtained her MD degree from Harvard Medical School and completed her radiation oncology residency and chief residency in the Harvard Radiation Oncology program. She serves as the departments associate director of translational medicine and the associate residency program director. 

Her primary research interests are focused on the reduction of late toxicity associated with radiotherapy for breast cancer.



Moderator
Clinical Research Workshop

Chairman
Debate
"All Breast Cancer Patients Should Have Germline Genetic Testing"

Virginia Kaklamani, MD
Professor
UT Health San Antonio MD Anderson Cancer Center

Dr Kaklamani is Professor of Medicine in the Division of Hematology/Oncology at UT Health San Antonio MD Anderson Cancer Center and is the Leader of the Breast Cancer Program. Dr Kaklamani completed her medical training with honors at the University of Athens and her residency in Internal Medicine at Newton-Wellesley Hospital in Boston, MA. She completed her fellowship in hematology/oncology at Northwestern University. She also received a Master of Science in Clinical Investigation from Northwestern University. She was Head of the Translational Breast Cancer Program at Northwestern University and co-director of the cancer genetics program at the same institution. Her research interests include studying high risk families and identifying genetic mutations that are associated with an increased risk for breast, colon and prostate cancer.  She has identified several genetic mutations related to obesity which increase the risk of breast cancer. Dr Kaklamani is a clinical investigator with expertise in designing clinical trials with targeted agents. 



Speaker
Educational Session
"Treatment of HER2-positive metastatic breast cancer - advances and challenges"

Nancy U. Lin, MD
Associate Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School

Nancy Lin, MD is the Associate Chief of Breast Medical Oncology for the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, Director of the Metastatic Breast Cancer Program, and an Associate Professor of Medicine at Harvard Medical School.  Her research is focused upon developing novel therapies for patients with metastatic breast cancer and in understanding mechanisms of therapeutic resistance. 

She has led multiple trials of novel systemic approaches for metastatic breast cancer, including patients with breast cancer brain metastases. She has had national and international leadership roles, including serving as the overall PI of several multi-center studies, co-chair of the Response Assessment in Neuro-Oncology metastatic working group, Chair of the Friends of Cancer-American Society Modernizing Eligibility Criteria Project-Brain Metastasis Working Group, and membership in national and international guidelines committees for the management of metastatic breast cancer. 

Dr. Lin is also experienced in tissue- and blood-based translational research, and with the construction and analysis of clinical databases.  She is the PI of the breast oncology-specific tissue banking protocol at Dana-Farber, Co-Chair of the Dana-Farber/Harvard Clinical Data and Tissue Users’ Committee, and PI of active protocols allowing prospective consent for research biopsies with linked clinical data across all stages of breast cancer, and of the EMBRACE (Ending Metastatic Breast Cancer for Everyone) metastatic cohort study. She serves as the DF/HCC institutional PI for the Translational Breast Cancer Research Consortium.  

Dr. Lin received her undergraduate degree from Stanford University and medical degree from Harvard Medical School. She subsequently completed her residency in Internal Medicine at Brigham and Women’s Hospital and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute.



Speaker
Translational Science Forum
"DNA replicative stress regulates responses to ICT in non-hypermutated tumors"

Shiaw-Yih Lin, PhD
Professor 
UT MD Anderson Cancer Center

Dr. Shiaw-Yih Lin is a tenured full professor in the Department of Systems Biology at MD Anderson Cancer Center. During his PhD studies at MD Anderson Cancer Center from 1996-1999, he carried out projects focused on the identification of novel cancer genes and biomarkers in breast cancer. As a postdoctoral fellow at Baylor College of Medicine (2000-2003), He trained with Dr. Stephen Elledge in the field of DNA damage response and cancer genetics. Since establishing his own research group at MD Anderson, he has built upon his research strengths in the areas of genome maintenance, systems and translational DNA repair and signature-guided precision cancer therapy. Dr. Lin's lab has identified many key players in DNA damage response network and characterized their critical roles in tumor suppression (e.g., Cancer Cell, 2006; Nat Cell Biol. 2009). Moreover, by utilizing powerful systems biology approaches, they have developed effective and novel strategies to target cancers via their defects of DNA damage and stress responses, including developing signatures and targeting drugs against cancer with homologous recombination (HR) defects (Nat Commu, 2014), mismatch repair (MMR) defects (Cancer Cell, 2020) and replication stress response (RSR) defects (Cell Rep, 2018). He has been playing an integral role in bridging the basic research with preclinical and clinical studies.His research accomplishments in these areas have led to his being awarded several major grants (NIH R01 grants, an Era of Hope Scholar Award and an Innovator and Scholar Concept Award from the DOD, and a Research Scholar Award from the American Cancer Society). All of these accomplishments demonstrate the high productivity of his research program.



Speaker
Educational Session
"Metastatic TNBC – What’s new on the horizon?"

Jennifer Litton, MD
Professor 
UT MD Anderson Cancer Center 

Jennifer Keating Litton, MD is Vice President, ad interim, of Clinical Research and a Professor in the Department of Breast Medical Oncology and Clinical Cancer Genetics at The University of Texas MD Anderson Cancer Center.  She holds an additional faculty position in the Graduate School of Biomedical Sciences at The University of Texas Health Sciences Center in Houston.  She attended Duke University, with degrees in English and in History and The University of Massachusetts Medical School.  After completing an Internal Medicine Residency at Baylor College of Medicine, she then served as Chief Medical Resident.  She completed a fellowship in Medical Oncology at The University of Texas MD Anderson Cancer Center before joining the faculty in the Department of Breast Medical Oncology where she is Chief, Section of Clinical Research and Drug Development.  Her research interests include the treatment of young breast cancer patients, including the treatment of breast cancer during pregnancy, treatment-related infertility, hereditary cancer syndromes, immunotherapy and triple negative breast cancer.  She is the principle investigator for multiple clinical trials.  She serves as a member of the National Cancer Center Network National Guidelines Panel for Hereditary Breast and Ovarian Cancer Syndromes as well as an Editor for the NIH Physician Data Query (PDQ) and has been appointed to the Breast Immuno-Oncology Task Force of the National Cancer Institute Breast Cancer Steering Committee and Co-Chair of the Society for Immunotherapy of Cancer (SITC) Breast Cancer Subcommittee.  She has authored multiple abstracts, peer-reviewed journal articles, and book chapters.  Dr. Litton has served on the boards of the St. Luke’s Episcopal Health Charities, the Children’s Fund, Suites of Hope and is an alumni of the Texas Lyceum.  

She lives in Houston with her husband Todd and their three children.



Speaker
Educational Session
"Rationale for combination therapies (including pre-clinical data)"

Sherene Loi, MBBS, FRACP, PhD
Professor of Oncology
Peter MacCallum Cancer Center 



Speaker
Educational Session
"Chromosomal instability and tumor immunity"

Mathieu Lupien, PhD
Senior Scientist
Princess Margaret Cancer Centre 



Moderator
Educational Session
"De-escalation of Surgical Therapy: What Does the Data Support"

Eleftherios P. Mamounas, MD, MPH
Director Comprehensive Breast Program
Orlando Health UF Health Cancer Center

Terry Mamounas, MD, MPH, FACS, received his medical degree from the University of Athens Medical School in Athens, Greece, in 1983 and a Masters of Public Health from the University of Pittsburgh in 1989. He completed his general surgery residency at McKeesport Hospital in Pennsylvania. He then completed a clinical oncology research fellowship at the University of Pittsburgh and a surgical oncology fellowship at the Department of Surgical Oncology, Roswell Park Cancer Institute in New York. He is currently the Medical Director or the Comprehensive Breast Program.

Dr. Mamounas has authored and coauthored more than 300 abstracts, peer-reviewed manuscripts and book chapters and has given numerous lectures at national and international meetings. As part of the National Surgical Adjuvant Breast and Bowel Project, his clinical research has been funded over the past 20 years by several National Cancer Institute grants and more recently by a Komen for the Cure grant. He has served on the editorial boards of several oncology journals and is a past associate editor of the Journal of Clinical Oncology. He has received several awards and distinctions and has been listed in The Best Doctors in America consistently since 2001. He is considered one of the nation's best cancer physicians.

Dr. Mamounas holds memberships in several professional societies, including the American College of Surgeons, the Society of Surgical Oncology and the American Society of Clinical Oncology. 



Speaker
Educational Session
"Tumor INF signaling - A double edged sword in cancer"

Sandra S. McAllister, PhD
Assistant Professor
Harvard Medical School



Speaker
Educational Session
"Special topics in metastatic ER+ breast cancer"

Ingrid A. Mayer, MD, MSCI
Professor of Medicine
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center



Speaker - Con
Educational Session
"DCIS"

Sarah McLaughlin, MD
Professor of Surgery
Mayo Clinic

Sarah McLaughlin is a Professor of Surgery at the Mayo Clinic in Jacksonville Florida. She graduated from the University of Missouri-Kansas City Medical School with distinction. She completed her General Surgery residency training at the Mayo Clinic in Florida and then a Breast Surgical Oncology fellowship at Memorial Sloan Kettering Cancer Center. She has an active breast surgery clinical and research practice and has a history of intramural, state and federal/NIH research funding with a specific focus on issues affecting breast cancer survivorship especially lymphedema diagnosis   and treatment.   

Dr. McLaughlin is a member of multiple national organizations and is a Fellow of the American College of Surgeons. She serves on several national committees interested in the education of breast surgeons, breast surgery and CGSO fellows, and general surgery residents. Within the Society of Surgical Oncology (SSO), she is the immediate past Chair of the Training Committee and in that role was involved in the organization of the Fellows Institutes I and II as well as the CGSO SSO Board Review course. She currently serves as a Councilor on Executive Council for the SSO. She also serves as an editorial board member for the Annals of Surgical Oncology. She has previously been a member of the SSO CME committee and the breast disease site work group. In addition, she is the Chair of The American Society of Breast Surgeons (ASBrS) Continuing Medical Education (CME) Committee, the Editor for the ASBrS Breast   Education Self-Assessment Program (BESAP), and a past member of the editorial board for the Surgical Council on Resident Education (SCORE) overseeing general surgery residency curriculum development. On behalf of the SSO and the ASBrS she is currently leading the task force to develop Focused Practice Designation in breast surgery criteria for the American Board of Surgery.  Previously she was the Program Chair for the 2015 ASBrS Annual Meeting. She also participated in   the creation, validation, implementation, and critical revision of the SSO/ASBrS breast surgery fellowship curriculum and case minimums in 2014 and 2019.   

Within the Mayo Clinic, she is a member of the Mayo Clinic Board of Governors and a member of the Florida Executive Operations leadership Team, Division Chair of General Surgery Mayo Clinic Florida, and the Medical Director of the Robert and Monica Jacoby Center for Breast Health.  She is the course director for the Mayo Clinic Multidisciplinary Update in Breast Health annual CME meeting and has served as the Program Director for the General Surgery Residency for 6 years. Further the Mayo Clinic has recognized Dr. McLaughlin as a Mayo Clinic Foundation Scholar, Outstanding Course Director, Faculty Teacher of the Year, and Outstanding CME Faculty. The city of Jacksonville recognizes Dr. McLaughlin as a Health care Hero for her contributions to the Jacksonville breast cancer community.   



Speaker
Plenary Lecture
"Local Regional Management Following Neoadjuvant Therapy: Minding the Knowledge Gaps"

Elizabeth A. Mittendorf, MD, PhD
Rob and Karen Hale Distinguished Chair in Surgical Oncology
Brigham and Women's Hospital
Dana-Farber Cancer Institute

Dr. Elizabeth Mittendorf is the Robert and Karen Hale Distinguished Chair in Surgical Oncology and Associate Chair for Research in the Department of Surgery at the Brigham and Women ' s Hospital. She is also the Director of the Breast lmmuno-Oncology program and Co-Director of the Breast Cancer Clinical Research Program at the Dana-Farber/Brigham and Women's Cancer Center. Dr. Mittendorf received her medical degree from Case Western Reserve University School of Medicine where she also completed a residency in General Surgery. She then served on active duty in the United States military before completing a fellowship in Surgical Oncology at the University of Texas MD Anderson Cancer Center. Dr. Mittendorf also holds a PhD in Immunology from the University of Texas Graduate School of Biomedical Sciences at Houston. She is board certified by the American Board of Surgery.   

Dr. Mittendorf focuses her clinical and laboratory efforts on the study of breast cancer with a specific interest in immunotherapy. She has been the principle on a number of clinical protocols including the phase Ill PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study, and a multicenter phase II trial investigating the efficacy of a CD8+ T cell eliciting vaccine in combination with trastuzumab which is based on preclinical data generated in her laboratory and follows a phase I trial she conducted demonstrating the combination to be safe.  This trial is supported by a Breakthrough Award from the Department of Defense. She was recently awarded a prestigious Stand Up to Cancer award to support the conduct of a multicenter trial evaluating the combination of ipatasertib and atezolizumab in triple negative breast cancer. This trial is also informed by work from her laboratory showing transcriptional regulation of PD-L1 expression through the P13K/AKT pathway. The current focus of her laboratory work is to determine the impact of standard and experimental therapies on immunologic aspects of the tumor microenvironment in order to inform rational trials of immunotherapeutic agents in breast cancer. She is also investigating novel targets for vaccine strategies in addition to her work evaluating breast tumor immunology and immunotherapy, 

Dr. Mittendorf has published extensively on a multitude of subjects related to breast cancer and surgical management of the disease to include incorporation of biologic factors into staging, management of the axilla, and surgery following receipt of neoadjuvant chemotherapy. 



Speaker - Con
Educational Session
"Exceptional responders to neoadjuvant chemotherapy"

Monica Morrow, MD
Chief, Breast Surgical Service
Memorial Sloan Kettering Cancer Center

Monica Morrow MD is Chief of the Breast Service at Memorial Sloan Kettering Cancer Center and the Anne Burnett Windfohr Chair of Clinical Oncology.  She is also Professor of Surgery at Weill Cornell Medical College.  She is the author of more than 500 peer reviewed publications, reviews and book chapters on topics related to the local therapy of breast cancer.  Her expertise has been recognized with the Gianni Bonadonna  Award from ASCO, the Susan G Komen Brinker Award for Scientific Distinction in Clinical Research, the William McGuire lectureship at SABCS, the John Wayne Clinical Research Award from the SSO, Presidency of the SSO, and the St. Gallen International breast Cancer Award. 



Moderator
Educational Session
"The Disparity Crisis in Breast Cancer"

Lisa Newman, MD, MPH
Chief, Breast Surgery
Weill Cornell Medicine
New York Presbyterian Network

Dr. Newman is a surgical oncologist with a practice dedicated to breast cancer management. In August 2018 she was appointed to oversee the breast program for the Weill Cornell Medicine-New York Presbyterian Hospital Network, serving its Manhattan, Queens and Brooklyn sites. Previously, she worked at the Henry Ford Health System, where she served as breast program director, covering multiple hospitals throughout Michigan since 2015. She is also the Founding Medical Director for the International Center for the Study of Breast Cancer Subtypes, currently headquartered at Weill Cornell Medicine. Dr.  Newman was Professor of Surgery and Director of the Breast Care Center for the University of Michigan in Ann Arbor, Michigan, where she also served as Program Director for the Breast Fellowship from 2002 to 2015. Dr. Newman holds a Masters Degree in Public Health from Harvard University, and she also obtained her undergraduate education at Harvard.  She attended medical school and completed her general surgery residency training at the State University of New York Downstate Medical Center in Brooklyn. Dr. Newman was remained at Downstate following completion of her postgraduate training, and served as an Assistant Professor of Surgery with this program for several years. She pursued fellowship training in surgical oncology at the M.D. Anderson Cancer Center 1997-99, followed by joining the faculty as an Assistant Professor; she continues to hold an Adjunct Professorship with M.D. Anderson. She has held Adjunct Professorships with the University of Michigan School of Public Health as well as the Department of Obstetrics and Gynecology. She served as Associate Director for the Walt Breast Center at Wayne State University/Karmanos Cancer Institute for two years after relocating to Michigan in 2000. 

Dr. Newman’s primary research has focused on race/ethnicity-related variation in breast cancer risk and outcome, the evaluation and management of high-risk patients; broadened applications for neoadjuvant chemotherapy, and special surgical techniques such as the skin-sparing mastectomy and lymphatic mapping/sentinel lymph node biopsy.  Her extensive research related to disparities in breast cancer risk and outcome has been published in numerous peer-reviewed medical journals and was featured in CNN’s documentary “Black in America 2”. She has also been the featured breast cancer medical expert for NBC’s “Today Show” (2014; 2017; 2019) as well on CBS Nightly News (2015). She maintains a very active community service record, and currently serves as Chief National Medical Advisor for the Sisters Network, Inc., a national African American breast cancer survivors support organization. 

She oversees an international breast cancer research and training program involving a network of physicians and facilities in Ghana, Ethiopia, Nigeria, Uganda, Mexico, and the Caribbean. This program has focused in the study of triple negative breast cancer in women with African ancestry. Her work has been acknowledged with several awards, such as “Top Blacks in Health Care 2018”; Phenomenal African American Women of 2018”; “Esteemed Women of Michigan 2018”; Crain’s “Health Care Hero” in 2017; 2012 Triple Negative Breast Cancer Foundation Hero Award; and the 2010 National Medical Association Woman in Medicine Award. She was named “Michiganders of the Year” in 2011; and an “Oprah’s Angels” for breast cancer work by Oprah magazine in 2012. She has received the University of Michigan 2012 Community Service Award; the 2013 Sarah Goddard Power Award for Advancement of Women in Academic Medicine; and the 2015 Harold Johnson Diversity Award. She has been named one of Detroit’s “Top Docs” and “Top Doctors of America” for several years. Dr. Newman has also been awarded the coveted title of Komen Scholar, and is a member of the Komen Scientific Advisory Board. Most recently, Dr. Newman was named a 2019 “Rock Star of Science and Medicine” by the European Society for Medical Oncology.”

Dr. Newman has been appointed to multiple national and regional leadership positions, including the CDC’s Advisory Committee on Breast Cancer in Young Women; the NIH’s Clinical Trials Advisory Committee; the Advisory Council to the National Institute of Minority Health and Disparities; chairperson for the Breast Committee of the Michigan Cancer Consortium. She has held leadership positions in the most prominent of oncologic academic and advocacy organizations: Society of Surgical Oncology (Executive Council; Disparities Committee chairperson); American Society of Clinical Oncology (Health Disparities Advisory Group chair; Health Services Committee chair); American Cancer Society (National Assembly;  Board of Directors for the Great Lakes Division); American College of Surgeons Oncology Group (Executive Council; Special Populations Committee chair). Dr. Newman’s editorial board service includes: Annals of Surgical Oncology (Breast Section Editor); Cancer (Disparities Section Editor); Journal of Clinical Oncology (Breast Section editorial board member) and she is currently on the editorial board for JAMA Surgery. Dr. Newman is chair of the AACR Regional Advisory Group on Africa, and she is co-Chair for the AACR 2020 Cancer Disparities Symposium. In October 2019 she was appointed 2nd Vice President-Elect for the American College of Surgeons.



Speaker
Educational Session
"DNA repair defect as a driver of therapy resistance"

Serena Nik-Zainal, MD, PhD
CRUK Advanced Clinician Scientist
University of Cambridge



Moderator
The Year in Review

Charles Kent Osborne, MD
Director
Dan L. Duncan Comprehensive Cancer Center
Baylor College of Medicine

Dr. C. Kent Osborne was born in 1946 in St. Louis, Missouri. He received his AB and MD degrees from the University of Missouri, both with honors. He completed his internship and residency at Johns Hopkins Hospital in 1974, and then spent three years as a clinical associate at the Medicine Branch, Breast Cancer Section of the National Cancer Institute in Bethesda, Maryland. In 1977, he took his first faculty position at The University of Texas Health Science Center at San Antonio, where he rose to the rank of Professor and became Director of the Division of Medical Oncology in 1992. In 1999, Dr. Osborne and his team moved to Baylor College of Medicine to develop a new multidisciplinary Breast Center and in 2005 he was named Director of the new Dan L Duncan Cancer Center at Baylor College of Medicine which achieved “comprehensive” designation under his leadership in 2015.

Dr. Osborne is a physician scientist who has focused on breast cancer his entire career. His research interests include understanding the biology of breast cancer and then developing new treatment approaches for the disease. He has published extensively on the mechanisms by which hormonal therapies such as tamoxifen inhibit breast cancer growth and how breast cancers become resistant to these therapies. He has also studied the role of various growth factors in breast cancer development and progression, and more recently how these other growth factors can interact with estrogen to stimulate tumor growth. His laboratory is also focusing on the mechanisms by which breast cancers develop resistance to HER2-targeted therapies. For more than a decade Dr. Osborne was Chairman of the Breast Cancer Committee for the Southwest Oncology Group, where he directed numerous nationwide clinical trials investigating new treatment strategies for breast cancer patients. He was the Principal Investigator of the Baylor Breast Cancer Specialized Program of Research Excellence grant (for the last 20 plus years) which has been funded since the Program began in 1992. He recently stepped down from SPORE, so he could focus on other BCM Cancer Center needs / projects. 

Among his previous awards are the Komen Foundation Award, the Brinker International Award for Breast Cancer Research, the European Institute of Oncology Annual Breast Cancer Award, and the ASCO Bonadonna Award for Breast Cancer Research. Most recently, he received the 2018 AACR Distinguished Award for Extraordinary Scientific Achievement and Leadership In Breast Cancer Research.

At Baylor College of Medicine, he is the Director of the Dan L Duncan Comprehensive Cancer Center and Professor of Medicine and Molecular and Cellular Biology. He currently holds the Tina and Dudley Sharp Chair in Oncology at Baylor College of Medicine. 



Speaker
Clinical Science Forum
"Interpreting reports"

Ben Ho Park, MD, PhD
Professor of Medicine
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center

Dr. Park attended The University of Chicago for his A.B. degree, followed by dual training at The University of Pennsylvania School of Medicine where he received both his M.D. and Ph.D. degrees. Dr. Park then trained in Internal Medicine and Hematology/Oncology at  The University of Pennsylvania prior to completing a post-doctoral fellowship in the laboratory of Dr. Bert Vogelstein at Johns Hopkins.   Dr. Park then joined the faculty in the Breast Cancer Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and was Professor of Oncology, Associate Director of Education and Research Training and Associate Dean of Postdoctoral Affairs for the School of Medicine prior to joining Vanderbilt University Medical Center in 2018. He is currently the Donna S. Hall Chair in Breast Cancer, Professor of Medicine and Associate Director for Basic and Translational Research in the Division of Heme/Onc, Co-Leader of the Breast Cancer Research Program, Associate Director for Translational Research and Director of Precision Oncology at the Vanderbilt-Ingram Cancer Center. His research program involves identifying and validating genetic targets for breast cancer therapy and diagnostics. In particular, Dr. Park has pioneered the use of “liquid biopsies” to help guide future management of breast cancer therapies. He has also led the formation and implementation of molecular tumor boards at Hopkins and other institutions, and more recently at the Vanderbilt-Ingram Cancer Center.



Speaker
Basic Science Forum
"Spatial variance signatures/Intra-tumor zonation in TNBC"

Morag Park, PhD
Director
McGill University
Goodman Cancer Research Centre 



Speaker
Translational Science Forum
"The making of an ADC"

Paul Parren, PhD
Head of R&D
Lava Therapeutics 



Speaker
Educational Session
"Body image and sexual health"

Ann H. Partridge, MD, MPH
Medical Oncologist
Dana-Farber Cancer Institute

Dr. Partridge received her MD from Cornell University Medical College in 1995. She completed her residency in internal medicine at the Hospital of the University of Pennsylvania and went on to complete fellowships in medical oncology and hematology at DFCI. Later she received an MPH from Harvard School of Public Health. She is a medical oncologist focusing on the care of women with breast cancer, and she has a particular interest in the psychosocial, behavioral, and communication issues in breast cancer care and treatment.



Moderator
Translational Science Forum
"Antibody-Drug Conjugates, Better Together"

Mark Pegram, MD
Associate Dean, Clinical Research Quality
Stanford University
Stanford Cancer Institute

Dr. Mark Pegram is the Susy Yuan-Huey Hung Professor of Medical Oncology, the Associate Director for Clinical Research at the Stanford Comprehensive Cancer Institute, and the Associate Dean for Clinical Research Quality at the Stanford University School of Medicine. Dr. Pegram has an extensive background with >25 years of experience in development of experimental therapeutics in the field of oncology, through the conduct of clinical/translational research studies. His initial foray into this field was as a member of the team (led by Dr. Dennis Slamon at UCLA, and a team of scientists at Genentech) that spearheaded the pre-clinical and clinical development of trastuzumab (Herceptin). Dr. Pegram's work was among the first to describe synergism between cytotoxic chemotherapeutic agents and anti-ERBB2 antibodies, and he was the lead author on the publication of the first human clinical trial to test the combination of chemotherapy plus Herceptin, which is now a backbone for ERBB2+ disease management. Dr. Pegram has been the principal investigator or co-principal investigator on numerous clinical/translational projects, many of which resulted in “first in human” phase I or IB clinical trials including SCH8500 (replication deficient adenovirus containing full-length p53 tumor suppressor gene cDNA), NB1011 (a thymidylate-synthase activated prodrug), AS1402 (humanized anti-muc1 monoclonal antibody), lapatinib (an ERBB2 kinase inhibitor), PR-104 (hypoxia-activated prodrug), AZD0530 (Src kinase inhibitor), bevacizumab (humanized anti-VEGF monoclonal antibody), pertuzumab (second generation anti-ERBB2 monoclonal antibody), MEDI-4276 (biparatopic, humanized anti-ERBB2 antibody drug conjugate), CD137-agonist antibody utolimumab, and humanized monoclonal antibody directed against CD47 (Hu5F9-G4). Dr. Pegram has contributed a recent invited review on the topic of HER2 antibody-drug conjugates.



Speaker
Translational Science Forum
"B-cells and follicular T cells regulate responses to ICT in hypermutated tumors"

Charles M. Perou, PhD
Professor 
University of North Carolina

Dr. Perou’s research crosses the disciplines of genomics, genetics, cancer biology, bioinformatics, epidemiology, and clinical research. A major contribution of his has been in the characterization of the genomic diversity of breast tumors, which resulted in the discovery of the intrinsic subtypes of breast cancer. He has authored more than 400 peer reviewed articles, and is an inventor on multiple USA and European patents. He is currently the Co-Director of the new Computational Medicine Program at UNC, Faculty Director of the Lineberger Comprehensive Cancer Center (LCCC) Bioinformatics Group, and Co-Leader of the LCCC Breast Cancer Research Program. He is the Vice Chair for Correlative Sciences for the ALLIANCE Breast Committee, and Steering Committee Member of the Translational Breast Cancer Research Consortium (TBCRC). His training history includes a Bachelor’s degree in Biology from Bates College, a PhD in Experimental Pathology from the University of Utah, and then postdoctoral work in the laboratory of David Botstein (then at Stanford University). He has won numerous awards including the 2009 AACR Outstanding Investigator Award for Breast Cancer Research, the 2011 Danaher Scientific and Medical Award, the 2012 European Institute of Oncology Breast Cancer Therapy Award, the 2016 Jill Rose Award for Distinguished Biomedical Research from the Breast Cancer Research Foundation, the 2016 Brinker Award for Scientific Distinction from the Susan G. Komen, and the 2018 Distinguished Scientist Award from the Association of American Cancer Institutes.  Lastly he has been named a Thomson Reuters Most Highly Cited Researcher in Clinical Medicine for 2014-18, where his work has received more than 145,000 total citations. 



Panelist
View From The Trenches - What Will You Do On Monday Morning?

Martine J. Piccart-Gebhart, MD, PhD
Scientific Director
Institut Jules Bordet

Martine J. Piccart, M.D., Ph.D., is honorary professor of oncology at the Université Libre de Bruxelles (ULB) and scientific director at the Jules Bordet Institute (Brussels/Belgium). Earning her medical degrees at ULB and oncology qualifications in New York and London, she is also a member of the Belgian Royal Academy of Medicine. She held presidencies of the European CanCer Organisation (ECCO), the European Organisation for the Research and Treatment of Cancer (EORTC), the European Society for Medical Oncology (ESMO) and served on the American Society of Clinical Oncology Board (ASCO). Presently she is a member of the Board of the American Association for Cancer Research (AACR) which nominated her as fellow of the AACR Academy in 2013.

A strong advocate for and leader of international research collaborations, Prof. Martine Piccart, together with Prof. Aron Goldhirsch, created the Breast International Group (BIG) in 1996 to foster collaboration and accelerate the development of better breast cancer treatments. The organisation, chaired by Prof. Piccart, became an international not-for-profit organization in 1999, and today unites 59 academic breast cancer research groups from around the world. BIG has more than 30 clinical trials under its umbrella at any one time, and several of BIG’s past studies are considered landmark and practice-changing.

Prof. Piccart’s relentless drive for results has made her an international leader, who has forged collaborations all over the world and has successfully managed a number of high-profile, Phase 3 clinical trials that have involved multiple international investigators and institutions. Those clinical trials include HERA (HERceptin Adjuvant), MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy), and ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation).

In 2014, BIG launched AURORA, an innovative molecular screening programme aiming to understand the molecular aberrations driving breast cancer metastasis and why tumours respond differently to therapy. Over 80 hospitals associated with 10 BIG research groups in 11 countries are taking part. Prof. Piccart believes this type of research will enable much more effective treatment of metastatic breast cancer in the future. 

Throughout her career, Prof. Piccart has been honoured with numerous prestigious awards for her research contributions, including the Jill Rose Award for distinguished biomedical research (2009, New York, USA), the William L. McQuire Award in recognition of her contribution in breast cancer research (2009, SABCS, San Antonio/Texas, USA), the Umberto Veronesi Award for the Future Fight Against Cancer (2012, Cancun, Mexico), the David A. Karnofsky Memorial Award in recognition of innovative clinical research and developments that have changed the way oncologists think about the general practice of oncology (2013, ASCO, Chicago, USA), the Susan G. Komen’s Brinker Award for Scientific Distinction (2015, SABCS, San Antonio/Texas, USA) and, the 2017 St. Gallen International Breast Cancer Award and most recently, the 2018 Prix Leopold Griffuel for translational and clinical research delivered by the “Association pour la Recherche sur le Cancer” in France and the KNAW Bob Pinedo Cancer Care Award in November 2018 in Amsterdam, Netherlands.

An accomplished clinician and scientist, Prof. Piccart is author or co-author of over 520 publications in peer-reviewed journals.  



Speaker
The Year in Review
"Basic science"

Helen Piwnica-Worms, PhD
Professor 
UT MD Anderson Cancer Center

 Dr. Piwnica-Worms is Professor of Experimental Radiation Oncology at the University of Texas MD Anderson Cancer Center. She is an American Cancer Society Research Professor and a member of the National Academy of Medicine. Dr. Piwnica-Worms completed a B.A. in Biology at St. Olaf College, a Ph.D. degree in microbiology and immunology at Duke University Medical School and a postdoctoral fellowship at the Dana-Farber Cancer Institute. She was Instructor of Pathology at the Dana-Farber Cancer Institute from 1988-1989 prior to moving to Tufts University Medical School where she was Assistant Professor of Physiology followed by Harvard Medical School and Beth Israel Hospital, Boston where she was Associate Professor of Microbiology and Molecular Genetics. In 1994, Dr. Piwnica-Worms moved to Washington University School of Medicine where she was the Gerty T. Cori Professor, an HHMI Investigator and served as Chair of the Department of Cell Biology and Physiology as well as Associate Director of Basic Science at the Alvin J. Siteman Comprehensive Cancer Center.  She relocated her research program to MD Anderson in 2013 where she holds the Senator A. M. Aikin Jr. Distinguished Chair.  Her laboratory focuses on identifying alterations with functional significance to the development and progression of breast cancer. A major effort is directed towards elucidating the contribution made by heterogeneity (genomic, phenotypic, spatial and compositional) in both the tumor and its microenvironment to cancer progression, metastasis and resistance to therapy. A second major effort is understanding how fasting and certain diets protect stem cells and promote organismal survival in the presence of lethal forms of DNA damage.



Speaker
Educational Session
"Personalized treatment of early stage HER2-positive breast cancer"

Aleix Prat, MD, PhD
Head Medical Oncology Department
Hospital Clínic Barcelona

Since 2014, Aleix Prat has been  the Head of the Medical Oncology Department of the Hospital Clínic Barcelona (Spain), Head of the Translational Genomics and Targeted Therapeutics in Solid Tumors Lab at IDIBAPS and Tenure-track 2 lecturer at the University of Barcelona. No more than 25% of his time is devoted to patient care and teaching and the remaining 75% of his time is focused on research activities which also include formal didactic work. Senior Specialist in Medical Oncology with a high medical training as evidenced by the 17th position out of num. 8,000 people in the Spanish National Medicine Exam (also known as MIR) obtained in 2003 and the 15 published articles in which he participate's actively during his residency in medical oncology at the Hospital Vall d'Hebron (Spain), under the supervision of Dr. Joseph Baselga (2004-2008). As scientific coordinator of the Scientific Board of the Spanish Breast Cancer Cooperative Research Group (SOLTI) that performs clinical trials of excellence in oncology, he was named member of the Executive Board of The Breast International Group (BIG) in 2018, an international non- profit organization that includes more than 56 cooperative groups from around the world. Since May 2019 he left the scientific coordination to assume the Presidency of the Governing Board of SOLTI. Over his career he obtained a world-wide prestige as a research scientist in the field of breast cancer genomics and biomarker development. Dr. Prat's interest in the genomic field grew out during his fellowship and after completing the Master of Molecular Oncology at the Spanish National Cancer Research Centre, CNIO (Madrid, 2008). During his fellowship at Vall d´Hebron, he published 15 articles, including 2 studies published in Annals of Oncology (IF: 7.040), where he established the value of a biomarker known as a CA-125 for predicting the risk of tumor recurrence in patients with ovarian cancer. In 2008, he became a postdoctoral research associate (2008-2012) at the Lineberger Comprehensive Cancer Center (University of North Carolina at Chapel Hill, USA) in the Laboratory of Prof. Charles M. Perou, a world- renowned translational researcher in breast cancer. During this postdoctoral experience, he discovered and characterized a new molecular subtype of breast cancer, known as a Claudin-low (Prat et al. Breast Cancer Research 2010; Citations: 1,518). In addition, he participated in The Cancer Genome Atlas breast cancer project (Nature 2012; Citations: 4,661), which is the most important molecular characterization study that has ever been performed in breast cancer. Since 2007, he has actively taken part in a total of 152 publications (43 as 1st author and 21 as senior author. 34 (†corresponding author) with a total impact factor of 1.411 and Score-H of 49 with 15.047 citations and140 communications in international congresses. Consequently, he has been invited to give conferences around the world as an expert in breast cancer genomics, moderator and discussan like ASCO Annual Meeting or San Antonio Breast Cancer Meeting (SABCS). In 2013, Dr. Prat presented the doctoral thesis at the Autonomous University of Barcelona (UAB) titled “Molecular characterization of the intrinsic subtypes of breast cancer” (qualification-cum laude), and was awarded the Extraordinary Prize of Doctorate in the field of Medicine.

As Tenure-track 2 lecturer in the University of Barcelona, he is particularly interested in education and teaching. In 2008, he published a self-assessment book for medical oncology fellows and physicians known as “OncoQuest”. This book was an instant hit with more than a 1,000 copies sold to date. Since 2014, he is an associate professor at the University of Barcelona and has directed 3 doctoral theses and currently supervising the PhD thesis of 3 students. His areas of interest are diagnostics and treatment of breast cancer and the subtypes of intrinsic breast cancer (Luminal A, Luminal B, HER2-enriched and basal-like). His research is leading is based on using genomic data to guide the design of clinical trials and biomarker development in order to identify more optimal treatments for patients with cancer. Specifically, its main strategic lines are: Assist in implementing and developing genomic platforms applicable in daily clinical practice; Participate in prospective and retrospective studies where scientists genomics of tumors analyzed; Validation of predictive genomic biomarkers and / or forecasts in clinical trials and evaluate gene expression data as a tool to identify new mechanisms of sensitivity/drug resistance and/or new therapeutic targets as immunotherapy.



Speaker
Educational Session
"Novel biomarkers in immune therapy response"

Lajos Pusztai, MD, DPhil
Professor of Medicine
Yale Cancer Center

Dr Pusztai is Professor of Medicine at Yale University, Director of Breast Cancer Translational Research and Co-Director of the Yale Cancer Center Genomics Genetics and Epigenetics Program. He is also Chair of the Breast Cancer Research Committee of the Southwest Oncology Group (SWOG). Dr. Pusztai received his medical degree from the Semmelweis University of Medicine in Budapest, and his D.Phil. degree from the University of Oxford in England. His research group has made important contributions to establish that estrogen receptor-positive and-negative breast cancers have fundamentally different molecular, clinical and epidemiological characteristics. He has been a pioneer in evaluating gene expression profiling as a diagnostic technology to predict chemotherapy and endocrine therapy sensitivity and have shown that different biological processes are involved in determining the prognosis and treatment response in different breast cancer subtypes. He made important contributions to clarify the clinical value of preoperative (neoadjuvant) chemotherapy in different breast cancer subtypes. Dr Pusztai is also principal investigator of several clinical trials investigating new drugs, including immunotherapies for breast cancer. He has published over 300 scientific manuscripts in high impact medical journals including the NEJM, JAMA, Journal of Clinical Oncology, Nature Biotechnology, PNAS, Lancet Oncology and JNCI. He is among the top 1% most highly cited investigators in clinical medicine according to a 2015 Thomson Reuters report. He is member of the Scientific Advisory Board of the Breast Cancer Research Foundation and a Susan Komen Scholar. 



Moderator
Educational Session
"Accelerating Recovery After Breast Cancer"

Susan W. Rafte, BA
Patient Advocate
Baylor College of Medicine

Susan Rafte is a 24-year metastatic breast cancer survivor. Since her diagnosis in 1994, she has been an active community volunteer, patient advocate and has dedicated and volunteered most of her time to raise awareness about breast health, provide peer-to-peer support to help others who have been touched by breast cancer and be the patient voice at the table to forward breast cancer research. Alongside her sister, Jane Weiner, they co-founded Pink Ribbons Project, a non-profit organization. During its 21-year existence it raised more than $6,000,000 to help in the fight against breast cancer. Several awards demonstrate her contributions in breast cancer advocacy and education. As an involved patient advocate and through her experiences that she has gained by being a part of the breast cancer community, she is enabled and qualified to serve as an advocate on scientific research committees to represent the voice of other patients and is experienced to be a mentor to review scientific grant applications to ensure terminology is understandable to a general, non-scientific audience and to convey the importance and overall impact of the project on breast cancer research and patient needs, concerns and care.

She can also develop and review the scientific sections to help communicate the importance of the project to breast cancer patients and their families and discuss other ways to be involved with the research grants. On a regular basis, she is committed to participate in meetings, to provide to the Investigators and others involved in the research, patient focused feedback and input on the impact of the project on patients by identifying the translational potential of this research. Susan Rafte is firmly committed to helping achieve the goals of breast cancer research.



Speaker
Educational Session
"Rescue DNA repair pathway and tumor immunity"

Manjeet K. Rao, PhD
Professor 
UT Health San Antonio

Their overall goal is to develop more potent and less toxic drugs for treating adult and pediatric cancer patients. They have employed unbiased high throughput genomewide functional screens as well as small molecule inhibitor screens to identify novel targets that may play critical roles in breast cancer, medulloblastoma, and osteosarcoma growth, progression and drug sensitivity.  Their research endeavors have resulted in clinical development of an anti-depression for treating triple negative breast cancer patients (https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2017-01937&r=1.). This study is a perfect example of bench to bedside initiative. In addition, they have made some major breakthrough in using miRNAs as therapeutic adjuvants for treating medulloblastoam and also breast cancers. Their ability to safely and effectively deliver microRNA using modified nanoparticle-based systemic delivery approaches have paved the way clinical development of candidate miRNAs in the near future. They are also actively engaged in understanding the role of RNA epigenetics, which has just begun to capture the imagination of scientific community, in cancer growth and progression. They were the first group to design novel algorithms that can identify transcriptome wide methylation as well as differential RNA methylation in normal and disease condition.   Recently, in a groundbreaking study, they showed that writers, erasers and readers of RNA methylation cross-talk with each other to maintain a level of RNA methylation that is critical for the stability of key progrowth/proliferation-specific genes and any pro-tumorigenic stimulus that perturbs that balance leads to uncontrolled expression/activity of those genes, resulting in tumor growth, angiogenesis, and progression. In addition to cancer, his group has made some seminal discoveries in the field of miRNA and development. They were the first group to develop an in vivo RNA interference (RNAi) approach that mimics the principle by which “microRNAs” are processed (Rao et al., Genes & Dev, 2006). Recently, in a groundbreaking work, they showed that LC3-associated phagocytosis is not only confined to macrophages but it is actively used by Sertoli cells to engulf and clear germ cell during germ cell differentiation and this process is regulated by microRNA. 

In addition to research, he is deeply involved in fulfilling the mission of Mays Cancer Center and serves as the Co-Leader of the Experimental and Developmental Therapeutics Program at the Mays Cancer Center.  He is also involved in the teaching and training mission at U.T. Health San Antonio and serves in a leadership role as a Discipline Director for the Cancer Biology (CB) track of the multidisciplinary graduate program at UTHSCSA. He also serves in a leadership role on the Committee on Graduate Studies (COGS) at UT Health San Antonio.



Panelist
View From The Trenches - What Will You Do On Monday Morning?

Meredith Regan, ScD
Associate Professor 
Dana-Farber Cancer Institute 



Moderator
Educational Session
"DNA Damage Repair"

Andrea Richardson, MD, PhD
Associate Professor of Pathology
Johns Hopkins Medicine

 Andrea Richardson MD, PhD is an anatomic pathologist with subspecialty training in breast pathology and cytopathology. She was a practicing physician and translational scientist at Brigham and Women's Hospital Harvard Medical School in Boston, MA for over 20 years. In 2015, she joined Johns Hopkins Medicine as Associate Professor and Director of Pathology for the JHM National Capital Region. She continues her translational breast cancer research with collaborators at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. Her research interests have focused on molecular pathology of breast cancer and development of predictive biomarkers of treatment response. 



Moderator
Educational Session
"Accelerating Recovery After Breast Cancer"

Moderator
Case Discussions

Mothaffar F. Rimawi, MD
Executive Medical Director of the Cancer Center
Baylor College of Medicine

Dr. Rimawi is a Professor, Medicine/Oncology, and Executive Medical Director of the Dan L Duncan Comprehensive Cancer Center (DLDCCC) at Baylor College of Medicine. He received his medical degree from the University of Jordan School of Medicine and completed his training in Internal Medicine, Medical Oncology, and Breast Oncology at Baylor College of Medicine.

His research is focused on designing and conducting biologically driven clinical trials to translate laboratory findings into new clinical treatments, and studying biomarkers of response and resistance. This will help elucidate mechanisms of therapeutic resistance to design more tailored treatment approaches, and to identify a treatment de-escalation strategy to spare patients unnecessary toxicity and cost when possible, without compromising outcomes.Dr. Rimawi has designed, led, and reported multiple biologically-driven national and international trials in breast cancer with special focus on translational work in HER2+ and in ER+ breast cancer. He serves on multiple national clinical research leadership committees including the Breast Committee of the NRG Oncology Group and is co-Chair of the HER2 Working group of the Translational Breast Cancer Symposium (TBCRC).



Panelist
View From The Trenches - What Will You Do On Monday Morning?

Valencia Robinson
Director
Florida Breast Cancer Foundation - Daytona Beach 



Moderator
Translational Science Forum
"Mechanisms of Response to Immune Checkpoint Therapies"

Jeffrey Rosen, PhD
CC Bell Distinguished Professor of Molecular & Cellular Biology
Baylor College of Medicine

Jeffrey Rosen studied chemistry at Williams College where he received a BA degree in 1966.  His Ph.D. research at the Roswell Park Cancer Institute helped elucidate the mechanisms for glucocorticoid resistance in lymphomas.  His postdoctoral studies at Vanderbilt University School of Medicine under the supervision of Dr. Bert W. O’Malley were concerned with the mechanism of action of estrogen in the chick oviduct.  His postdoctoral studies involved the isolation of ovalbumin mRNA and the first demonstration of steroid hormone induction of a specific mRNA.  

He joined the faculty of Baylor College of Medicine in 1973, and was a founder member of the first Department of Cell Biology in the USA.  In 1987-88 he spent a sabbatical leave in the laboratories of Drs. George Stark and Ian Kerr at the Imperial Cancer Research Laboratories funded by an American Cancer Society Scholar Grant, where he participated in early studies to elucidate the mechanisms of interferon action that helped lead to the discovery of the Jak/Stat pathway.  Dr. Rosen is currently a Distinguished Service Professor, the  Vice Chair and the C.C. Bell Professor of Molecular & Cellular Biology and Medicine at Baylor College of Medicine.  He was the recipient of two MERIT awards from the National Cancer Institute on a grant entitled, “Hormonal Regulation of Breast Cancer” currently in its forty-fourth year of consecutive funding.  His laboratory has authored 300 publications and book chapters. He is the PI on the CPRIT BCM Comprehensive Cancer Training Program.    Dr. Rosen has trained 37 graduate students and 45 postdoctoral fellows many of whom are now faculty at major academic institutions in the USA and abroad.  He has received the Marc Dresden Excellence in Graduate Education Award, the Barbara & Corbin J. Robertson, Jr. Presidential Award for Excellence in Education at BCM, the Endocrine Society Edwin B. Astwood Lecture Award, the Michael E. DeBakey, M.D., Excellence in Research Award, the Susan G. Komen for the Cure Brinker Basic Science Award, and the AACR Distinguished Lectureship in Breast Cancer Research.  He is also an AAAS Fellow.   

Dr. Rosen is the co-leader of Breast Program of the Dan L. Duncan NCI-designated Comprehensive Cancer Center.  



Moderator
Educational Session
"Tumor Inflammation (and Metastasis)"

Speaker
Educational Session

"HER2 targeted therapy: Determinates of response and mechanisms of resistance"

Rachel Schiff, PhD
Associate Professor 
Baylor College of Medicine

Dr. Schiff is an Associate Professor at the Baylor College of Medicine, Lester & Sue Smith Breast Center and the Departments of Medicine and Molecular and Cellular Biology. She is an internationally recognized expert in breast cancer translational research with extensive experience in preclinical in vivo therapeutic and resistance models for various targeted therapies, as well as in correlative studies and associated biomarkers in clinical trials. Dr. Schiff received her PhD from the Hebrew University Hadassah Medical School in Jerusalem and completed her post-doctoral fellowship at the University of Texas Health Science Center, San Antonio. Dr. Schiff's research focuses on understanding the key signaling pathways in breast cancer and on identifying therapeutic strategies to overcome them, particularly treatments targeting the estrogen receptor and the HER2 receptor. Major research themes include the crosstalk between the ER signaling network and growth factor and cellular kinase pathways, the role of ER co-regulators and pioneer factors in breast cancer development and progression, the identification of genomic and epigenomic alterations underlying resistance to endocrine and HER2-targeted therapies, and the development of biomarkers for tailored therapeutic interventions. Dr. Schiff's research is partly supported by grants from the National Cancer Institute, The Breast Cancer Research Foundation, Susan G. Komen for the Cure, and the Department of Defense Breast Cancer Research Program. Dr. Schiff has co-authored over 100 peer-reviewed manuscripts and several book chapters in key textbooks in the breast cancer field.  



Speaker
Plenary Lecture
"Is There a Future for Cooperative Group Trials?"

Norman E. "Ned" Sharpless, MD
Director
National Cancer Institute



Speaker
Mini-Symposium
"Aging"

Mike Stratton, FMedSci, FRS
Director 
Wellcome Sanger Institute 



Speaker
Workshop
"Research technology for clinicians (CTCs, cfDNA, Crispr)"

Nicholas Turner, PhD, FRCP, BM, MA
Consultant Medical Oncologist
The Royal Marsden Hospital

Professor Nicholas Turner is a Consultant Medical Oncologist who specialises in the treatment of breast cancer. He read Natural Sciences at Cambridge University before qualifying in 1997 from the University of Oxford Medical School. After completing general medical training in London, he trained in medical oncology at Royal Free and University College Hospitals and completed a PhD at The Institute of Cancer Research in 2006. He joined the Breast Unit of The Royal Marsden as a Consultant in Medical Oncology in 2008.

He is a Team Leader in Molecular Oncology at the Breast Cancer Now Research Centre at the Institute of Cancer Research (ICR). He is Genotyping, Phenotyping and Cancer Evolution Theme Lead for The Royal Marsden and ICR NIHR Biomedical Research Centre.

Professor Turner is the Breast Domain Lead of the Genomics England Clinical Interpretation Partnerships, and has co-chaired of the ASCO/CAP review committee on circulating tumor DNA analysis in patients with cancer. He sits on the organising committees of many international conferences on breast cancer, was the executive chair of the IMPAKT 2015 breast cancer conference, and is a scientific editor of the journal Cancer Discovery. He is Chief Investigator of a number of national and international trials of precision therapy in breast cancer. His research interests include the development of new therapies for breast cancer and using liquid biopsies to deliver more precise treatment for breast cancer.



Speaker
Mini-Symposium
"BRCA/HRD"

Andrew Tutt, MB ChB, MRCP, FRCR, PhD
Head of Division of Breast Cancer Research
Institute of Cancer Research

Professor Andrew Tutt qualified in medicine in 1990. After postgraduate training in General Medicine, he trained in clinical oncology at the The Royal Marsden NHS Foundation Trust before gaining a Doctoral Research Training Fellowship from the Medical Research Council to work in Professor Alan Ashworth’s laboratory at The Institute of Cancer Research, London. Here, he worked on the then-unknown DNA repair functions of the BRCA2 breast cancer predisposition gene and was awarded his PhD in 2002. 

In his postdoctoral work as a Clinician Scientist he identified the synthetic lethality between PARP inhibitors and BRCA1/2 mutations with Dr Chris Lord and Professor Alan Ashworth. He went on to design the Single Agent Proof of Concept Phase I trials and associated DNA repair biomarker studies with the ICR and The Royal Marsden Drug Development Unit, and has since led international Phase II and III trials for BRCA1/BRCA2-associated malignancy.  

He cares for women with breast cancer as a Consultant Oncologist in the multidisciplinary Breast Unit at Guy’s and St Thomas’ NHS Foundation Trust. He is Professor of Breast Oncology and Director of the Breast Cancer Now Research Unit at King’s College London and has recently been appointed Director of the Breast Cancer Now Toby Robins Research Centre, Head of the Division of Breast Cancer Research and Professor of Breast Oncology at the ICR.  Professor Tutt has developed a translational laboratory for triple negative breast cancer. He leads a clinical trial programme focusing on TNBC and cancers associated with functional deficiencies in BRCA1 and BRCA2. He also leads translational laboratories at both the ICR and KCL, studying BRCA1 and BRCA2 associated TNBC forms of breast cancer. Andrew’s group publishes in high impact journals regularly and amongst their latest work they published a new TNBC target, PIM1 kinase, in Nature Medicine in November 2016. 

He is Chief Investigator for the recently reported multicentre UKCRN ”Triple Negative Trial” and is Global Study Chair of the ‘OlympiA’ study – an adjuvant PARP inhibitor trial in patients with germline BRCA 1/2 mutations and breast cancer.  He has been a Visiting Professor at British Columbia Cancer Agency, Jean Lubrano Visiting Scholar at Harvard Medical School, and is a member of the St Gallen Early Breast Cancer International Consensus Panel and recently received the Addarii Award for his work in the field of breast and ovarian cancer research. 



Moderator
View From The Trenches - What Will You Do On Monday Morning?

Steven Vogl, MD
Physician
Scarsdale, NY

Dr. Vogl first suggested a critical review meeting at the end of SABCS just after the 2015 meeting and participated in the first two "View From The Trenches" meetings in 2016 and 2017. He is well known at SABCS for frequently asking key questions after presentations. 

He has been in solo private practice of general medical oncology for 38 years. Before that he was an academic oncologist who who designed and analyzed studies in lung, head and neck and gynecologic cancers in the Eastern Cooperative Oncology Group where he served on several site-specific committees in the group.



Speaker
Educational Session
"EMT"

Jing Yang, PhD
Professor 
University of California, San Diego

Dr. Jing Yang is a Professor of Pharmacology and Pediatrics at the University of California, San Diego, La Jolla, CA. 

Their general research interest is to understand the molecular basis of tumor metastasis. They utilize cell and molecular biology tools, mouse tumor models, functional genomics, and 2D/3D imaging techniques to uncover the genes and the signaling pathways responsible for tumor metastasis. Specifically, they have identified two cellular programs, Epithelial to Mesenchymal Transition (EMT) and invadopodia-mediated extracellular matrix degradation as being critical for tumor invasion and metastasis. They continue to dissect the signaling pathways regulating these programs and to test the importance of these signaling pathways in tumor metastasis in both mouse tumor models and human tumor samples.  



Moderator
Mini-Symposium
"Mechanisms of Mutagenesis in Breast Cancer"

Douglas Yee, MD
Director
Masonic Cancer Center 
University of Minnesota

Dr. Douglas Yee is director of the Masonic Cancer Center, University of Minnesota. A professor in the Departments of Medicine and Pharmacology, Dr. Yee holds the John H. Kersey Chair in Cancer Research. He is internationally known for his laboratory research on the growth regulation of tumors by the insulin-like growth factors and the clinical translation of these findings. Dr. Yee has a leadership role in the I-SPY 2 trial which is designed to validate investigational therapies in the neoadjuvant treatment of breast cancer. He is chair of the I-SPY 2 Agent Selection Committee and serves on its Executive and Data Access and Publication Committees. Further, he is the coordinating investigator for the BoehringerIngelheim phase 1b study of xentuzamab. Dr. Yee’s curriculum vitae includes well over 230 publications. He also maintains an active clinical practice in breast medical oncology at the Breast Center, University of Minnesota Medical Center.

Dr. Yee graduated from the University of Michigan in Ann Arbor, earned his medical degree from the University of Chicago,and completed his residency in internal medicine at the University of North Carolina in Chapel Hill and completed his fellowship in medical oncology at the National Cancer Institute in Bethesda, MD. Before coming to the University of Minnesota, he held faculty positions in the Lombardi Cancer Center at Georgetown University in Washington, D.C., and at the University of Texas Health Science Center in San Antonio.



Moderator
Educational Session
"New Frontiers in Immunotherapy"

Speaker
Educational Session
"New targets in myeloid cells"

Xiang Zhang, PhD
Professor 
Baylor College of Medicine

Dr. Xiang Zhang obtained his Ph.D. degree from Columbia University in 2006, and did his postdoctoral training at Memorial Sloan Kettering Cancer Center from 2006 to 2011. He was then recruited to the Breast Center of Baylor College of Medicine as a McNair Scholar, and is now a tenured associate professor. His lab focuses on metastatic breast cancer, and has made seminal contributions in two areas: 1) bone metastasis and 2) tumor immunology and immunotherapies. In the former, he discovered the osteogenic niche that promotes early-stage bone colonization, and invented a series of pre-clinical models and technologies to accelerate anti-metastasis drug discovery . In the latter, he uncovered the link between oncogenic mTOR signaling and recruitment of myeloid-derived suppressor cells  and a mutual regulatory loop between tumour vasculature and immunostimulatory reprogramming. These discoveries have made significant impacts in our understanding of tumor-microenvironment interactions and the consequent effects on therapies. 

Dr. Zhang is the first or corresponding author of 18 papers published in journals including Cell, Nature, Cancer Cell, Nature Cell Biology, Developmental Cell, Nature Communications, Genes and Development, PNAS, Genome Research and MCB. He also co-authored another 40 papers published in Cell, Nature, Cancer Cell, Nature Medicine and etc. He was the invited speakers of a number of international conferences including the Breast Cancer Think Tank (2012, 2014, 2016, 2017), Gordon Conference on Bone and Teeth Biology (2014), Gordon Conference on Mammary Gland Biology (2010 and 2019) and Advanced Breast Cancer First Consensus (2011). His awards include “Thesis with Distinction” by Columbia University (2006), the McNair Scholarship by Baylor College of Medicine (2011), Pathway to Independence Award by NCI (2010-2014), DoD BCRP Era of Hope Scholarship (2016), Excellent in Research Award of MCB, BCM (2016), Theresa Foundation Leadership Award (2016),  Susan G. Komen Career Catalyst Award (2014-2017), Michael DeBakey Award for Excellence in Research by Baylor College of Medicine (2018), and Sue Eccles Young Investigator Award of Metastasis Research Society (2018). He is a co-director of the annual Metastatic Breast Cancer Conference (2014-2019). He is the ad hoc reviewer of Science, Cell, Nature Medicine, Nature Cell Biology, Caner Cell, Cell Stem Cell, JEM, Cancer Research, RNA, Nucleic Acid Research, BMC Bioinformatics, Breast Cancer Cancer Research and Treatment and Breast Cancer Research, and is an active member of American Association of Cancer Research (since 2012), Metastasis Research Society (since 2015), and American Association of Immunology (since 2016).

In collaboration with  Astro     and     SSO